Celcuity Stock News

78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D)MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology

MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treati

MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating

MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treat

(PR-inside.com) MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team. Michael Snitkovsky joined Celcuity as VP of Program Management and David Bridge joined as VP of Quality Assurance and Process Development. "We are pleased to welcome Michael and David to the Celcuity leadership team. Each brings extensive experience across the biopharmaceutical development spectrum, and each has a fantastic track record," said Brian Sullivan, Celcuity''s Chief Executive Officer and co-founder. ..

Renaissance Technologies LLC trimmed its holdings in Celcuity Inc. (NASDAQ:CELC) by 43.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 34,256 shares of the companys stock after selling 26,500 shares during the period. Renaissance Technologies LLCs holdings in Celcuity were worth $822,000 at the end of the most recent reporting period. Several other []

Geode Capital Management LLC lifted its stake in Celcuity Inc. (NASDAQ:CELC) by 159.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 127,112 shares of the companys stock after purchasing an additional 78,113 shares during the period. Geode Capital Management LLC owned approximately []

MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treat

(PR-inside.com) MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to provide Ibrance® (palbociclib) for use in Celcuity''s Phase 3 clinical trial at no cost to Celcuity. As previously disclosed, Celcuity expects to initiate a Phase 3 clinical trial in the first half of 2022 to evaluate gedatolisib, the company''s pan-PI3K/mTOR inhibitor, in combination with palbociclib, a CDK4/6 inhibitor, and Faslodex® (fulvestrant), a selective endocrine receptor ..

Zacks Investment Research lowered shares of Celcuity (NASDAQ:CELC) from a hold rating to a sell rating in a research note released on Friday, Zacks.com reports. According to Zacks, Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer []

JPMorgan Chase & Co. lifted its holdings in Celcuity Inc. (NASDAQ:CELC) by 234,200.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,372 shares of the companys stock after purchasing an additional 9,368 shares during the quarter. JPMorgan Chase & Co.s holdings in Celcuity []

MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2021 Results - Earnings Call Transcript

MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating

The shares of Celcuity Inc (NASDAQ: CELC) have received a price target of $50. These are the details.